Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
Seeking Alpha11/5/2026Neutral
ACAD
ACADIA Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.66B
P/E Ratio
10.01
EPS
$2.12
Beta
0.89
52W High
$30.96
52W Low
$18.39
50-Day MA
$22.86
200-Day MA
$23.54
Dividend Yield
—
Profit Margin
30.10%
Forward P/E
21.01
PEG Ratio
50.86
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $1.20B |
| Gross Profit (TTM) | $768.42M |
| EBITDA | $134.72M |
| Operating Margin | 20.90% |
| Return on Equity | 31.40% |
| Return on Assets | 4.89% |
| Revenue/Share (TTM) | $7.03 |
| Book Value | $8.04 |
| Price-to-Book | 2.63 |
| Price-to-Sales (TTM) | 3.04 |
| EV/Revenue | 2.288 |
| EV/EBITDA | 20.37 |
| Quarterly Earnings Growth (YoY) | -26.20% |
| Quarterly Revenue Growth (YoY) | 22.80% |
| Shares Outstanding | $172.31M |
| Float | $128.52M |
| % Insiders | 0.33% |
| % Institutions | 98.94% |
Historical Volatility
HV 10-Day
26.55%
HV 20-Day
37.73%
HV 30-Day
32.27%
HV 60-Day
44.78%
HV Rank
21.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($30.53 target)
4
Strong Buy10
Buy5
Hold1
SellLatest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire10/29/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire10/22/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
GlobeNewsWire10/20/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire10/15/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire10/13/2026Neutral
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
Zacks Investment Research10/13/2026Positive
4 CNS Drug Stocks Worth Watching This World Mental Health Day
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
Zacks Investment Research10/9/2026Positive
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire10/8/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire10/6/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACAD and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026